Our company was co-founded in 2005 by Dr. Frank Longo, a neurologist and neuroscientist who chaired the Department of Neurology and Neurological Sciences at Stanford University and by Anne Chun Longo, who served as senior director of development for neurosciences at Stanford University.
We are a clinical-stage biopharmaceutical company focused on developing disease-modifying, small molecule, oral drugs that target the mechanisms underlying neurodegenerative and other neurological disorders. Our primary goal is to promote neurological health through “synaptic resilience,” specifically by modulating neurotrophin receptors expressed by neurons and immune cells.
Our core technology revolves around targeting neurotrophin receptors — specifically the p75, TrkB, and TrkC receptors — which regulate signaling networks that influence whether neurons and their synapses survive or degenerate, as well as immune cell functions. Our lead candidate, LM11A-31, targets the p75 receptor and has shown disease modification and efficacy in preclinical models of Alzheimer’s, other tauopathies, HIV dementia, Huntington’s disease, and several other conditions. In addition, LM11A-31 has shown considerable promise in a Phase 2a Alzheimer’s disease clinical trial. A key advantage of LM11A-31 is its ability to cross the blood-brain barrier when administered orally as a simple pill, a critical property for the treatment of brain diseases.
